EA201390066A1 - КОМБИНАЦИИ АГОНИСТОВ β-3-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ГИПЕРАКТИВНОСТИ МОЧЕВОГО ПУЗЫРЯ - Google Patents

КОМБИНАЦИИ АГОНИСТОВ β-3-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ГИПЕРАКТИВНОСТИ МОЧЕВОГО ПУЗЫРЯ

Info

Publication number
EA201390066A1
EA201390066A1 EA201390066A EA201390066A EA201390066A1 EA 201390066 A1 EA201390066 A1 EA 201390066A1 EA 201390066 A EA201390066 A EA 201390066A EA 201390066 A EA201390066 A EA 201390066A EA 201390066 A1 EA201390066 A1 EA 201390066A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
combinations
hyperactivity
antagonists
treatment
Prior art date
Application number
EA201390066A
Other languages
English (en)
Other versions
EA030145B1 (ru
Inventor
Стивен Калтабиано
Элиот Олстейн
Стюарт Маккалум
Original Assignee
Олтеркс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Олтеркс, Инк. filed Critical Олтеркс, Инк.
Publication of EA201390066A1 publication Critical patent/EA201390066A1/ru
Publication of EA030145B1 publication Critical patent/EA030145B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены фармацевтические комбинации, содержащие агонист β-3-адренергических рецепторов и антагонист мускариновых рецепторов, и способы их применения. Предложенные комбинации содержат солабегрон и оксибутинин. Также предложены способы применения фармацевтических комбинаций для лечения одного или более симптомов, связанных с гиперактивностью мочевого пузыря, например частоты императивных позывов к мочеиспусканию, никтурии и недержания мочи.
EA201390066A 2010-08-03 2011-08-02 Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря EA030145B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37017110P 2010-08-03 2010-08-03
PCT/US2011/046208 WO2012018773A1 (en) 2010-08-03 2011-08-02 Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder

Publications (2)

Publication Number Publication Date
EA201390066A1 true EA201390066A1 (ru) 2013-07-30
EA030145B1 EA030145B1 (ru) 2018-06-29

Family

ID=44511540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390066A EA030145B1 (ru) 2010-08-03 2011-08-02 Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря

Country Status (19)

Country Link
US (1) US8642661B2 (ru)
EP (1) EP2600859A1 (ru)
JP (2) JP2013535486A (ru)
KR (2) KR20130135239A (ru)
CN (1) CN103269692B (ru)
AP (1) AP2013006742A0 (ru)
AR (1) AR084122A1 (ru)
AU (1) AU2011285928B9 (ru)
BR (1) BR112013002511A2 (ru)
CA (1) CA2807135C (ru)
CL (1) CL2013000342A1 (ru)
CO (1) CO6680685A2 (ru)
EA (1) EA030145B1 (ru)
MX (1) MX353105B (ru)
NZ (1) NZ607485A (ru)
PE (1) PE20131341A1 (ru)
SG (2) SG187689A1 (ru)
TW (1) TW201208667A (ru)
WO (1) WO2012018773A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2016004056A1 (en) * 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
US20150306090A1 (en) * 2012-08-31 2015-10-29 Astellas Pharma Inc. Orally administered medical composition
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
RU2702106C2 (ru) * 2014-08-26 2019-10-04 Астеллас Фарма Инк. Производное 2-аминотиазола или его соль
MX2017007054A (es) * 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
WO2017066572A1 (en) 2015-10-15 2017-04-20 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
IL310527A (en) 2015-10-23 2024-03-01 B3Ar Therapeutics Inc Zwitterion solvegron and its uses
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EP3463307A4 (en) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
WO2024086240A1 (en) * 2022-10-18 2024-04-25 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (ru) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
EP0940387B1 (en) 1995-10-26 2003-05-07 Mitsubishi Pharma Corporation Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2004285289A1 (en) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
AU2008233232A1 (en) * 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
JP2011516482A (ja) 2008-04-04 2011-05-26 メルク・シャープ・エンド・ドーム・コーポレイション β３アドレナリン作動性受容体アゴニストとしてのヒドロキシメチルピロリジン
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2010129326A1 (en) 2009-05-08 2010-11-11 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
AU2010286694B2 (en) 2009-08-27 2013-09-12 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
ES2819054T3 (es) 2009-10-02 2021-04-14 Delta T Llc Cerca de aire para aspa de ventilador
CN102638987A (zh) * 2009-10-07 2012-08-15 默沙东公司 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
AU2011285928A1 (en) 2013-03-07
JP2017002074A (ja) 2017-01-05
TW201208667A (en) 2012-03-01
CA2807135C (en) 2019-05-14
JP6441267B2 (ja) 2018-12-19
KR20180008918A (ko) 2018-01-24
JP2013535486A (ja) 2013-09-12
BR112013002511A2 (pt) 2017-06-27
PE20131341A1 (es) 2013-12-07
MX353105B (es) 2017-12-19
SG187689A1 (en) 2013-03-28
AU2011285928B9 (en) 2018-08-02
AU2011285928B2 (en) 2016-06-16
MX2013001342A (es) 2013-03-22
US20120035118A1 (en) 2012-02-09
CN103269692A (zh) 2013-08-28
CL2013000342A1 (es) 2013-06-28
WO2012018773A1 (en) 2012-02-09
US8642661B2 (en) 2014-02-04
SG10201506076TA (en) 2015-09-29
AR084122A1 (es) 2013-04-24
KR20130135239A (ko) 2013-12-10
CN103269692B (zh) 2018-02-23
AP2013006742A0 (en) 2013-02-28
CO6680685A2 (es) 2013-05-31
EA030145B1 (ru) 2018-06-29
CA2807135A1 (en) 2012-02-09
EP2600859A1 (en) 2013-06-12
NZ607485A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
EA201390066A1 (ru) КОМБИНАЦИИ АГОНИСТОВ β-3-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ГИПЕРАКТИВНОСТИ МОЧЕВОГО ПУЗЫРЯ
EA201290266A1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
EA201001256A1 (ru) Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
CL2011002418A1 (es) Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar transtornos proliferativos.
EA201201357A1 (ru) Антитела к cd40
EA201400579A1 (ru) Антитела к il-36r
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
MX2011012691A (es) Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
UY34561A (es) Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica.
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
EA200870409A1 (ru) Антагонисты киназы pi3
AR075812A1 (es) Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201790309A1 (ru) Антитела к fap, способы их получения и применения
EA201300530A1 (ru) Антитела к il-23
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
NZ605928A (en) Chimeric il-1 receptor type i agonists and antagonists